ClinicalTrials.gg
CompletedNCT00782184Updated May 16, 2024Results posted

Ezetimibe/Simvastatin (10 mg/40 mg) vs. the Doubling of Atorvastatin in High Risk Participants (MK-0653A-134 AM1)(COMPLETED)

A Phase 3 interventional study of ezetimibe/simvastatin 10/40 and atorvastatin 40 mg in Hypercholesterolemia, sponsored by Organon and Co. Completed. Open to participants aged 18 Years to 79 Years. Per ClinicalTrials.gov, last updated 2024-05-16.

Sponsored by Organon and Co · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
250
Allocation
Randomized
Ages
18 Years to 79 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 77 studies testing atorvastatin in Hypercholesterolemia — 1 open to participants now, 1 under way, none of them phase 3. Atorvastatin · Hypercholesterolemia.

Enrollment
33rd of 75
250 · median 148
Started
2008
with 12 others
Phase 3
31 of 77
none open now
Registered
33rd of 77
by date
Lead sponsor
16 of 77
Organon and Co

Among the 77 studies testing atorvastatin in Hypercholesterolemia, this one is the 33rd largest by enrollment of the 75 interventional ones that give a count, is one of 13 that started in 2008, is one of 31 in phase 3, and was the 33rd registered.

Hypercholesterolemia

1,177 studies on the registry are indexed under Hypercholesterolemia; 95 are open to participants now.

Browse Hypercholesterolemia studies →

Open to participants now

1 of the 77 studies testing atorvastatin in Hypercholesterolemia is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

About atorvastatin

Atorvastatin: first FDA approval 1996 (LIPITOR). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 55 Hypercholesterolemia studies recruiting now, 23 (42%) set no upper age limit and 20 (36%) stop at 75 or younger; 9 take children under 18; 11 take healthy volunteers.

This study: 18 Years to 79 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 77 studies testing atorvastatin in Hypercholesterolemia, or all of them as a file.
02

Study summary

Participants currently taking atorvastatin 20 mg will be switched to either atorvastatin 40 mg or ezetimibe/simvastatin 10 mg/40 mg (10/40). After 6 weeks of treatment, the percent reduction in low-density lipoprotein cholesterol (LDL-C) will be assessed and compared between the two treatment groups.

03

Conditions studied

  • Hypercholesterolemia
04

Who can participate

Ages eligible
18 Years to 79 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participants who are either statin naive or on approved lipid lowering therapy for 6 weeks prior to study initiation
  • Participant meets Adult Treatment Panel (ATP) III High Risk criteria

Exclusion criteria

Exclusion Criteria:

  • Females who are pregnant or breastfeeding
  • Participant consumes more than 14 alcoholic beverages per week
  • Participant has been treated with an drug within the last 30 days
  • Participant has congestive heart failure ( [NYHA] Type III or IV)
  • Participant has had gastric bypass
  • Participant is newly diagnosed with type 1 or 2 diabetes
  • Participant is (HIV) positive
  • Participant has a history of drug or alcohol abuse within the last 5 years
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
250 participants (actual)

Study arms

  • Experimental
    ezetimibe/simvastatin 10/40

    Participants received 20 mg open-label atorvastatin during a 5-week run-in period. Following this run-in period, ezetimibe/simvastatin 10/40 was administered once daily in tablet form during the 6-week double-blind treatment period

    Drug: ezetimibe/simvastatin 10/40 · Drug: atorvastatin 20 mg

  • Active comparator
    atorvastatin 40 mg

    Participants received 20 mg open-label atorvastatin during a 5-week run-in period. Following this run-in period, 40 mg atorvastatin was administered once daily in tablet form during the 6-week double-blind treatment period

    Drug: atorvastatin 40 mg · Drug: atorvastatin 20 mg

Interventions

  • Drugezetimibe/simvastatin 10/40

    ezetimibe/simvastatin 10/40 tablet once daily for 6 weeks.

    Also known as: Vytorin

  • atorvastatin 40 mg tablet once daily for 6 weeks

    Also known as: Lipitor

  • All participants will take atorvastatin 20 mg tablet once daily for the 5 week run-in period before randomization

    Also known as: Lipitor

06

What researchers measure

Primary outcomes

  1. Percent Change From Baseline in Low Density Lipoprotein (LDL)-C

    Time frame: Baseline (Treatment Day 1), Treatment Week 6

Secondary outcomes

  1. Number of Participants Reaching LDL-C Target Goals of <70 mg/dL

    Target LDL-C level of \< 70 mg/dL (1.81 mmol/L) at study endpoint after 6 weeks of treatment for the Full Analysis Set (FAS) population.

    Time frame: Treatment Week 6

  2. Number of Participants Reaching LDL-C Target Goal <77 mg/dL

    Target LDL-C level of \< 77 mg/dL (2.00 mmol/L) at study endpoint after 6 weeks of treatment for the Full Analysis Set (FAS) population.

    Time frame: Treatment Week 6

  3. Number of Participants Reaching LDL-C Target Goal <100 mg/dL

    Target LDL-C level of \< 100 mg/dL (2.59 mmol/L) at study endpoint after 6 weeks of treatment for the Full Analysis Set (FAS) population.

    Time frame: Treatment Week 6

  4. Percent Change From Baseline in Total Cholesterol

    Time frame: Baseline (Treatment Day 1), Treatment Week 6

  5. Percent Change From Baseline in Triglycerides

    Time frame: Baseline (Treatment Day 1), Treatment Week 6

  6. Percent Change From Baseline in High-Density Lipoprotein (HDL) Cholesterol

    Time frame: Baseline (Treatment Day 1), Treatment Week 6

  7. Percent Change From Baseline in Non-HDL Cholesterol

    Time frame: Baseline (Treatment Day 1), Treatment Week 6

  8. Percent Change From Baseline in LDL-Cholesterol/HDL-Cholesterol Ratio

    Time frame: Baseline (Treatment Day 1), Treatment Week 6

  9. Percent Change From Baseline in Total Cholesterol/HDL-Cholesterol Ratio

    Time frame: Baseline (Treatment Day 1), Treatment Week 6

  10. Percent Change From Baseline in Non-HDL Cholesterol/HDL-Cholesterol Ratio

    Time frame: Baseline (Treatment Day 1), Treatment Week 6

  11. Percent Change From Baseline in Apolipoprotein B

    Time frame: Baseline (Treatment Day 1), Treatment Week 6

  12. Percent Change From Baseline in Apolipoprotein A-1

    Time frame: Baseline (Treatment Day 1), Treatment Week 6

  13. Percent Change From Baseline in Apolipoprotein B/A-1 Ratio

    Time frame: Baseline (Treatment Day 1), Treatment Week 6

  14. Percent Change From Baseline in High-sensitivity C-Reactive Protein (Hs-CRP)

    Time frame: Baseline (Treatment Day 1), Treatment Week 6

07

Results

Posted Oct 31, 2011

Participant flow

Participant flow — Overall Study
MilestoneEzetimibe/Simvastatin 10/40Atorvastatin 40 mg
Started120130
Completed116125
Not completed45
Withdrew: Adverse event12
Withdrew: Protocol violation01
Withdrew: Withdrawal by subject32

Outcome measures

SecondaryNumber of Participants Reaching LDL-C Target Goals of <70 mg/dL

Target LDL-C level of \< 70 mg/dL (1.81 mmol/L) at study endpoint after 6 weeks of treatment for the Full Analysis Set (FAS) population.

Time frame:
Treatment Week 6
Reported as:
Number · participants
Number of Participants Reaching LDL-C Target Goals of <70 mg/dL
participantsEzetimibe/Simvastatin 10/40Atorvastatin 40 mg
Number of Participants Reaching LDL-C Target Goals of <70 mg/dL346
Statistical analysis
  • Ezetimibe/Simvastatin 10/40 vs Atorvastatin 40 mg · Regression, Logistic · p = <0.001 · Odds ratio (or): 8.4 · 95% CI 3.4 to 21.0
PrimaryPercent Change From Baseline in Low Density Lipoprotein (LDL)-C
Time frame:
Baseline (Treatment Day 1), Treatment Week 6
Reported as:
Least squares mean · percent change from baseline
Percent Change From Baseline in Low Density Lipoprotein (LDL)-C
percent change from baselineEzetimibe/Simvastatin 10/40Atorvastatin 40 mg
Percent Change From Baseline in Low Density Lipoprotein (LDL)-C-26.81 ± 27.09-11.81 ± 22.85
Statistical analysis
  • Ezetimibe/Simvastatin 10/40 vs Atorvastatin 40 mg · Longitudinal Data Analysis (LDA) Model · p = <0.001 · Difference in least squares means: -15.00 · 95% CI -21.15 to -8.84
SecondaryNumber of Participants Reaching LDL-C Target Goal <77 mg/dL

Target LDL-C level of \< 77 mg/dL (2.00 mmol/L) at study endpoint after 6 weeks of treatment for the Full Analysis Set (FAS) population.

Time frame:
Treatment Week 6
Reported as:
Number · participants
Number of Participants Reaching LDL-C Target Goal <77 mg/dL
participantsEzetimibe/Simvastatin 10/40Atorvastatin 40 mg
Number of Participants Reaching LDL-C Target Goal <77 mg/dL4511
Statistical analysis
  • Ezetimibe/Simvastatin 10/40 vs Atorvastatin 40 mg · Regression, Logistic · p = <0.001 · Odds ratio (or): 6.7 · 95% CI 3.3 to 13.9
SecondaryNumber of Participants Reaching LDL-C Target Goal <100 mg/dL

Target LDL-C level of \< 100 mg/dL (2.59 mmol/L) at study endpoint after 6 weeks of treatment for the Full Analysis Set (FAS) population.

Time frame:
Treatment Week 6
Reported as:
Number · participants
Number of Participants Reaching LDL-C Target Goal <100 mg/dL
participantsEzetimibe/Simvastatin 10/40Atorvastatin 40 mg
Number of Participants Reaching LDL-C Target Goal <100 mg/dL8152
Statistical analysis
  • Ezetimibe/Simvastatin 10/40 vs Atorvastatin 40 mg · Regression, Logistic · p = <0.001 · Odds ratio (or): 3.5 · 95% CI 2.0 to 6.0
SecondaryPercent Change From Baseline in Total Cholesterol
Time frame:
Baseline (Treatment Day 1), Treatment Week 6
Reported as:
Least squares mean · percent change from baseline
Percent Change From Baseline in Total Cholesterol
percent change from baselineEzetimibe/Simvastatin 10/40Atorvastatin 40 mg
Percent Change From Baseline in Total Cholesterol-15.97 (-19.17 to -12.76)-7.73 (-10.91 to -4.55)
Statistical analysis
  • Ezetimibe/Simvastatin 10/40 vs Atorvastatin 40 mg · LDA Model · p = <0.001 · Difference in least squares means: -8.24 · 95% CI -12.50 to -3.97
SecondaryPercent Change From Baseline in Triglycerides
Time frame:
Baseline (Treatment Day 1), Treatment Week 6
Reported as:
Least squares mean · percent change from baseline
Percent Change From Baseline in Triglycerides
percent change from baselineEzetimibe/Simvastatin 10/40Atorvastatin 40 mg
Percent Change From Baseline in Triglycerides-5.41 (-11.36 to 0.95)-7.54 (-13.32 to -1.38)
Statistical analysis
  • Ezetimibe/Simvastatin 10/40 vs Atorvastatin 40 mg · LDA Model · p = 0.593 · Difference in least squares means: 2.13 · 95% CI -5.67 to 9.93
SecondaryPercent Change From Baseline in High-Density Lipoprotein (HDL) Cholesterol
Time frame:
Baseline (Treatment Day 1), Treatment Week 6
Reported as:
Least squares mean · percent change from baseline
Percent Change From Baseline in High-Density Lipoprotein (HDL) Cholesterol
percent change from baselineEzetimibe/Simvastatin 10/40Atorvastatin 40 mg
Percent Change From Baseline in High-Density Lipoprotein (HDL) Cholesterol5.37 (2.39 to 8.35)2.89 (-0.07 to 5.85)
Statistical analysis
  • Ezetimibe/Simvastatin 10/40 vs Atorvastatin 40 mg · LDA Model · p = 0.211 · Difference in least squares means: 2.48 · 95% CI -1.41 to 6.37
SecondaryPercent Change From Baseline in Non-HDL Cholesterol
Time frame:
Baseline (Treatment Day 1), Treatment Week 6
Reported as:
Least squares mean · percent change from baseline
Percent Change From Baseline in Non-HDL Cholesterol
percent change from baselineEzetimibe/Simvastatin 10/40Atorvastatin 40 mg
Percent Change From Baseline in Non-HDL Cholesterol-22.50 (-26.78 to -18.22)-10.88 (-15.13 to -6.64)
Statistical analysis
  • Ezetimibe/Simvastatin 10/40 vs Atorvastatin 40 mg · LDA Model · p = <0.001 · Difference in least squares means: -11.62 · 95% CI -17.32 to -5.92
SecondaryPercent Change From Baseline in LDL-Cholesterol/HDL-Cholesterol Ratio
Time frame:
Baseline (Treatment Day 1), Treatment Week 6
Reported as:
Least squares mean · percent change from baseline
Percent Change From Baseline in LDL-Cholesterol/HDL-Cholesterol Ratio
percent change from baselineEzetimibe/Simvastatin 10/40Atorvastatin 40 mg
Percent Change From Baseline in LDL-Cholesterol/HDL-Cholesterol Ratio-28.77 (-33.78 to -23.76)-12.66 (-17.63 to -7.69)
Statistical analysis
  • Ezetimibe/Simvastatin 10/40 vs Atorvastatin 40 mg · LDA Model · p = <0.001 · Difference in least squares means: -16.10 · 95% CI -22.77 to -9.44
SecondaryPercent Change From Baseline in Total Cholesterol/HDL-Cholesterol Ratio
Time frame:
Baseline (Treatment Day 1), Treatment Week 6
Reported as:
Least squares mean · percent change from baseline
Percent Change From Baseline in Total Cholesterol/HDL-Cholesterol Ratio
percent change from baselineEzetimibe/Simvastatin 10/40Atorvastatin 40 mg
Percent Change From Baseline in Total Cholesterol/HDL-Cholesterol Ratio-18.63 (-22.37 to -14.89)-8.60 (-12.31 to -4.89)
Statistical analysis
  • Ezetimibe/Simvastatin 10/40 vs Atorvastatin 40 mg · LDA Model · p = <0.001 · Difference in least squares means: -10.02 · 95% CI -14.96 to -5.08
SecondaryPercent Change From Baseline in Non-HDL Cholesterol/HDL-Cholesterol Ratio
Time frame:
Baseline (Treatment Day 1), Treatment Week 6
Reported as:
Least squares mean · percent change from baseline
Percent Change From Baseline in Non-HDL Cholesterol/HDL-Cholesterol Ratio
percent change from baselineEzetimibe/Simvastatin 10/40Atorvastatin 40 mg
Percent Change From Baseline in Non-HDL Cholesterol/HDL-Cholesterol Ratio-24.41 (-29.40 to -19.43)-11.20 (-16.15 to -6.25)
Statistical analysis
  • Ezetimibe/Simvastatin 10/40 vs Atorvastatin 40 mg · LDA Model · p = <0.001 · Difference in least squares means: -13.21 · 95% CI -19.83 to -6.59
SecondaryPercent Change From Baseline in Apolipoprotein B
Time frame:
Baseline (Treatment Day 1), Treatment Week 6
Reported as:
Least squares mean · percent change from baseline
Percent Change From Baseline in Apolipoprotein B
percent change from baselineEzetimibe/Simvastatin 10/40Atorvastatin 40 mg
Percent Change From Baseline in Apolipoprotein B-17.23 (-20.84 to -13.62)-9.53 (-13.12 to -5.95)
Statistical analysis
  • Ezetimibe/Simvastatin 10/40 vs Atorvastatin 40 mg · LDA Model · p = 0.002 · Difference in least squares means: -7.69 · 95% CI -12.50 to -2.88
SecondaryPercent Change From Baseline in Apolipoprotein A-1
Time frame:
Baseline (Treatment Day 1), Treatment Week 6
Reported as:
Least squares mean · percent change from baseline
Percent Change From Baseline in Apolipoprotein A-1
percent change from baselineEzetimibe/Simvastatin 10/40Atorvastatin 40 mg
Percent Change From Baseline in Apolipoprotein A-12.56 (0.36 to 4.77)-2.69 (-4.88 to -0.50)
Statistical analysis
  • Ezetimibe/Simvastatin 10/40 vs Atorvastatin 40 mg · LDA Model · p = <0.001 · Difference in least squares means: 5.25 · 95% CI 2.44 to 8.06
SecondaryPercent Change From Baseline in Apolipoprotein B/A-1 Ratio
Time frame:
Baseline (Treatment Day 1), Treatment Week 6
Reported as:
Least squares mean · percent change from baseline
Percent Change From Baseline in Apolipoprotein B/A-1 Ratio
percent change from baselineEzetimibe/Simvastatin 10/40Atorvastatin 40 mg
Percent Change From Baseline in Apolipoprotein B/A-1 Ratio-18.59 (-22.70 to -14.48)-5.67 (-9.76 to -1.59)
Statistical analysis
  • Ezetimibe/Simvastatin 10/40 vs Atorvastatin 40 mg · LDA Model · p = <0.001 · Difference in least squares means: -12.91 · 95% CI -18.31 to -7.52
SecondaryPercent Change From Baseline in High-sensitivity C-Reactive Protein (Hs-CRP)
Time frame:
Baseline (Treatment Day 1), Treatment Week 6
Reported as:
Least squares mean · percent change from baseline
Percent Change From Baseline in High-sensitivity C-Reactive Protein (Hs-CRP)
percent change from baselineEzetimibe/Simvastatin 10/40Atorvastatin 40 mg
Percent Change From Baseline in High-sensitivity C-Reactive Protein (Hs-CRP)-6.18 (-20.49 to 10.70)-8.86 (-22.67 to 7.41)
Statistical analysis
  • Ezetimibe/Simvastatin 10/40 vs Atorvastatin 40 mg · LDA Model · p = 0.785 · Difference in least squares means: 2.68 · 95% CI -16.50 to 21.86

Adverse events

Non-serious events are listed at a 5.0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Ezetimibe/Simvastatin 10/40—1/119 (0.8%)0/119 (0%)
Atorvastatin 40 mg—1/130 (0.8%)2/130 (1.5%)
Placebo—0/1 (0%)1/1 (100%)
Most frequent serious events
Most frequent serious events
EventEzetimibe/Simvastatin 10/40Atorvastatin 40 mgPlacebo
urinary tract infectionInfections and infestations1/1190/1300/1
back painMusculoskeletal and connective tissue disorders0/1191/1300/1
Most frequent other events
Most frequent other events
EventEzetimibe/Simvastatin 10/40Atorvastatin 40 mgPlacebo
ConstipationGastrointestinal disorders0/1192/1301/1

Baseline characteristics

Age, Continuous
Age, Continuous(years)Ezetimibe/Simvastatin 10/40Atorvastatin 40 mgTotal
Mean58.9 ± 10.059.7 ± 8.459.3 ± 9.2
Sex: Female, Male
Sex: Female, Male(Participants)Ezetimibe/Simvastatin 10/40Atorvastatin 40 mgTotal
Female5765122
Male6365128
08

Study locations

No study locations are listed for this record.

09

References and documents

Publications

  • Hing Ling PK, Civeira F, Dan AG, Hanson ME, Massaad R, De Tilleghem Cle B, Milardo C, Triscari J. Ezetimibe/simvastatin 10/40 mg versus atorvastatin 40 mg in high cardiovascular risk patients with primary hypercholesterolemia: a randomized, double-blind, active-controlled, multicenter study. Lipids Health Dis. 2012 Jan 31;11:18. doi: 10.1186/1476-511X-11-18. PubMed 22293030 ↗

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Nov 2008, a primary completion of Sep 2010 and a completion of Sep 2010. It does not say whether these dates are actual or estimated.

Results were first posted in Oct 2011, 1 year 1 month after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 29, 2008
First posted
Oct 31, 2008
Start
Nov 2008
Primary completionActual
Sep 2010
CompletionActual
Sep 2010
Results first posted
Oct 31, 2011
Last update
May 16, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 16, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00782184
Lead sponsor
Organon and Co
Responsible party
Sponsor
First posted
Oct 31, 2008
Start date
Nov 2008
Primary completion
Sep 2010
Completion
Sep 2010
Results posted
Oct 31, 2011
Last update
May 16, 2024

Study contacts

Medical Monitor
study director · Merck Sharp & Dohme LLC

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Atorvastatin

Start the discussion